Quelle place en oncologie thoracique pour la tomographie par émission de positons au 18FDG (TEP-FDG) en 2010 ?
作者： F. Vaylet , J. Margery , G. Bonardel , H. Le Floch , F. Rivière
DOI: 10.1016/J.PNEUMO.2010.07.010
关键词:
摘要: Resume En dix ans, la tomographie par emission de positons (TEP) au 18F-fluor-deoxy-glucose (FDG) a pris une place incontournable dans prise en charge des pathologies malignes du poumon, plevre et mediastin. De nombreuses publications grande envergure, meta-analyses recommandations societes savantes europeennes, nord-americaines japonaises ont bien precise ses indications son impact medicoeconomique. Elle constitue base bilans diagnostiques d’extension ces cancers radiotherapie, d’autant plus depuis l’apparition cameras hybrides associant les signaux TEP TDM. Si aujourd’hui sa valeur predictive negative est le point fort, l’apport nouveaux marqueurs devrait permettre d’ameliorer sensibilite diagnostique specificite preciser l’appreciation l’evaluation reponse aux differentes therapeutiques.
em-consulte.com
elsevier.com参考文章(152)
Zhen-jiang ZHANG, Jing-han CHEN, Long MENG, Jia-jun DU, Lin ZHANG, Ying LIU, Hong-hai DAI, 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer. Chinese Medical Journal. ,vol. 120, pp. 125- 131 ,(2007) , 10.1097/00029330-200701020-00010
Peter Darroch Hollett, J. Scott Sloka, Maria Mathews, Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada Medical Science Monitor. ,vol. 10, ,(2004)
Donald A. Podoloff, Ritsuko Komaki, Franklin C.L. Wong, David J. Yang, Tomio Inoue, Pedro Bassa, E. Edmund Kim, Wai-Hoi Wong, Keigo Endo, Detecting recurrent or residual lung cancer with FDG-PET The Journal of Nuclear Medicine. ,vol. 36, pp. 788- 793 ,(1995)
Hongming Zhuang, Yan Xiu, Abass Alavi, Justin Kung, Amol Takalkar, Jian Q. Yu, Scott Potenta, Ghassan El-Haddad, Rakesh Kumar, 18F-FDG PET in Evaluation of Adrenal Lesions in Patients with Lung Cancer The Journal of Nuclear Medicine. ,vol. 45, pp. 2058- 2062 ,(2004)
J F Vansteenkiste, S G Stroobants, P R De Leyn, P J Dupont, J Bogaert, A Maes, G J Deneffe, K L Nackaerts, J A Verschakelen, T E Lerut, L A Mortelmans, M G Demedts, Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. Journal of Clinical Oncology. ,vol. 16, pp. 2142- 2149 ,(1998) , 10.1200/JCO.1998.16.6.2142
G Bonardel, L Vedrine, O Aupee, E Gontier, P Le Garlantezec, M Soret, H Foehrenbach, Évaluation par tomographie par émission de positons des traitements en cancérologie : vers la personnalisation thérapeutique Bulletin Du Cancer. ,vol. 96, pp. 213- 226 ,(2009) , 10.1684/BDC.2008.0816
Malgorzata Beryt, Mark D. Pegram, Johannes Czernin, Amanda L. Kesner, Michael E. Phelps, Wei-Ann Hsueh, Anne Gangloff, Daniel H.S. Silverman, Predicting Chemotherapy Response to Paclitaxel with 18F-Fluoropaclitaxel and PET The Journal of Nuclear Medicine. ,vol. 47, pp. 1995- 1999 ,(2006)
Joubin Meta, Johannes Czernin, Christiaan Schiepers, Sanjiv S. Gambhir, Cecelia S. Yap, Michael E. Phelps, Marc A. Seltzer, Jyotsna Rao, Daniel H. Silverman, Peter E. Valk, The Impact of PET on the Management of Lung Cancer: The Referring Physician’s Perspective The Journal of Nuclear Medicine. ,vol. 43, pp. 752- 756 ,(2002)
Andrea Schaefer-Schuler, Carl-Martin Kirsch, Christian Rübe, Dirk Hellwig, Christiane Sebastian-Welsch, Stephanie Kremp, Ursula Nestle, Comparison of Different Methods for Delineation of 18F-FDG PET–Positive Tissue for Target Volume Definition in Radiotherapy of Patients with Non–Small Cell Lung Cancer The Journal of Nuclear Medicine. ,vol. 46, pp. 1342- 1348 ,(2005)
Mithat Gönen, Heiko Schöder, Screening for Cancer with PET and PET/CT: Potential and Limitations The Journal of Nuclear Medicine. ,vol. 48, pp. 4- 18 ,(2007)